Sartorius Stedim: Q1 underlying EPS down 35%
(CercleFinance.com) - Sartorius Stedim Biotech has reported Q1 2023 underlying EPS of E1.
43, down 35.3% y-o-y, with underlying EBITDA down 27.5% to E220m, i.e. a margin of 30.3%.
The pharmaceutical industry supplier reported sales of E726m, down 15.8%, including an 18.4% organic decline (-17.2% at constant exchange rates), with a normalisation in demand.
Acknowledging uncertainties of the global political and economic situation which remain significant, the group has confirmed that it anticipates moderate sales growth in 2023 and a profit margin as high as that recorded in 2022.
Copyright (c) 2023 CercleFinance.com. All rights reserved.